Publications

BibTex format

@article{Cortellini:2022:10.1038/s41416-022-01952-x,
author = {Cortellini, A and Aguilar-Company, J and Salazar, R and Bower, M and Sita-Lumsden, A and Plaja, A and Lee, AJX and Bertuzzi, A and Tondini, C and Diamantis, N and Martinez-Vila, C and Prat, A and Apthorp, E and Gennari, A and Pinato, DJ},
doi = {10.1038/s41416-022-01952-x},
journal = {British Journal of Cancer},
pages = {1787--1792},
title = {Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer},
url = {http://dx.doi.org/10.1038/s41416-022-01952-x},
volume = {127},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundConsolidated evidence suggests spontaneous immunity from SARS-CoV-2 is not durable, leading to the risk of reinfection, especially in the context of newly emerging viral strains. In patients with cancer who survive COVID-19 prevalence and severity of SARS-CoV-2 reinfections are unknown.MethodsWe aimed to document natural history and outcome from SARS-CoV-2 reinfection in patients recruited to OnCovid (NCT04393974), an active European registry enrolling consecutive patients with a history of solid or haematologic malignancy diagnosed with COVID-19.ResultsAs of December 2021, out of 3108 eligible participants, 1806 COVID-19 survivors were subsequently followed at participating institutions. Among them, 34 reinfections (1.9%) were reported after a median time of 152 days (range: 40–620) from the first COVID-19 diagnosis, and with a median observation period from the second infection of 115 days (95% CI: 27–196). Most of the first infections were diagnosed in 2020 (27, 79.4%), while most of reinfections in 2021 (25, 73.5%). Haematological malignancies were the most frequent primary tumour (12, 35%). Compared to first infections, second infections had lower prevalence of COVID-19 symptoms (52.9% vs 91.2%, P = 0.0008) and required less COVID-19-specific therapy (11.8% vs 50%, P = 0.0013). Overall, 11 patients (32.4%) and 3 (8.8%) were fully and partially vaccinated against SARS-CoV-2 before the second infection, respectively. The 14-day case fatality rate was 11.8%, with four death events, none of which among fully vaccinated patients.ConclusionThis study shows that reinfections in COVID-19 survivors with cancer are possible and more common in patients with haematological malignancies. Reinfections carry a 11% risk of mortality, which rises to 15% among unvaccinated patients, highlighting the importance of universal vaccination of patients with cancer.
AU  - Cortellini,A
AU  - Aguilar-Company,J
AU  - Salazar,R
AU  - Bower,M
AU  - Sita-Lumsden,A
AU  - Plaja,A
AU  - Lee,AJX
AU  - Bertuzzi,A
AU  - Tondini,C
AU  - Diamantis,N
AU  - Martinez-Vila,C
AU  - Prat,A
AU  - Apthorp,E
AU  - Gennari,A
AU  - Pinato,DJ
DO  - 10.1038/s41416-022-01952-x
EP  - 1792
PY  - 2022///
SN  - 0007-0920
SP  - 1787
TI  - Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-022-01952-x
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000842858300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.nature.com/articles/s41416-022-01952-x
UR  - http://hdl.handle.net/10044/1/103451
VL  - 127
ER  -

Download

Dr. David James PINATO

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)